MannKind

MannKind Rule of 40

The Rule of 40 of MannKind (MNKD) as of Nov 3, 2026 is 33.35 %. In the previous year, Rule of 40 was 68.92 % — a change of -51.62% (lower).

Rule of 40

33.35 %

YoY

-51.62%

Last updated:

Rule of 40 of MannKind is 2025 33.35 % . Rule of 40 of MannKind was 2024 68.92 % . It decreases by -51.62% lower compared to the previous year.

The MannKind Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
-142.05 USD
Jan 1, 2019
59.66 USD
Jan 1, 2020
-70.32 USD
Jan 1, 2021
-69.49 USD
Jan 1, 2022
-33.05 USD
Jan 1, 2023
103.78 USD
Jan 1, 2024
68.92 USD
Jan 1, 2025
33.35 USD
The MannKind Rule of 40 history
YEARRule of 40YoY
33.35 %-51.62%
68.92 %-33.59%
103.78 %-414.05%
-33.05 %-52.44%
-69.49 %-1.19%
-70.32 %-217.88%
59.66 %-142.00%
-142.05 %-85.52%
-981.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MannKind Stock analysis

What does MannKind do? MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MannKind stock

Rule of 40 of MannKind is 33.35 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 MannKind since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — MannKind

All Key Metrics — MannKind